OBERLIN, Ohio, April 5, 2023 /PRNewswire/ -- Synapse Biomedical, Inc. announced today that the FDA has granted premarket approval (PMA) of the NeuRx ® Diaphragm Pacing System (NeuRx DPS ®) for use in ...
Please provide your email address to receive an email when new articles are posted on . Synapse Biomedical has received premarket approval from the FDA for its NeuRx Diaphragm Pacing System, which ...
Synapse Biomedical Inc. has won breakthrough device designation from the FDA for its Transaeris system, a diaphragm pacing system (DPS) for use in weaning patients off mechanical ventilation. The ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The new marketing approval ...